Launch of Biotie/Lundbeck's Selincro will see a paradigm shift in alcohol addiction market

10 May 2013

US and European psychiatrists and US managed care organization (MCO) pharmacy directors surveyed by advisory firm Decision Resources agree that a therapy's ability to support abstinence is one of the attributes that most influences their decisions regarding prescribing and formulary status determinations, respectively, in the treatment of alcohol addiction.

Historically, therapies for alcohol addiction have been indicated for the support of abstinence - however, Finland-based Biotie (Nasdaq-OMX; BTH1V) and Lundbeck's (LUND: C) Selincro (nalmefene) recently received approval from the European Medicines Agency for reducing alcohol consumption in adult alcohol-dependent patients who have a high level of alcohol consumption, and marketers are hopeful that physicians will accept harm reduction as a meaningful treatment goal in Europe.

The DecisionBase 2013 report - titled Alcohol Addiction: How Would a Harm Reduction Treatment Paradigm Be Received by Physicians? - also finds that surveyed US psychiatrists indicated that they would prescribe Alkermes' samidophan to 25% of their patients with alcohol addiction, if it were to proceed in development and launch for alcohol addiction in the USA.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK